169 related articles for article (PubMed ID: 11761819)
1. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
[TBL] [Abstract][Full Text] [Related]
2. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
[TBL] [Abstract][Full Text] [Related]
3. Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo.
Cattaneo C
Minerva Med; 2001 Aug; 92(4):277-84. PubMed ID: 11535971
[TBL] [Abstract][Full Text] [Related]
4. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Malerba M; Ponticiello A; Radaeli A; Bensi G; Grassi V
Pulm Pharmacol Ther; 2004; 17(1):27-34. PubMed ID: 14643168
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
6. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
Murali PM; Rajasekaran S; Paramesh P; Krishnarajasekar OR; Vasudevan S; Nalini K; Lakshmisubramanian S; Deivanayagam CN
Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
[TBL] [Abstract][Full Text] [Related]
7. [Antioxidative features of ambroxol--usefulness in COPD].
Nowak D
Pneumonol Alergol Pol; 2001; 69(9-10):590-3. PubMed ID: 11928667
[No Abstract] [Full Text] [Related]
8. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis].
Michnar M; Milanowski J
Pneumonol Alergol Pol; 1996; 64 Suppl 1():90-6. PubMed ID: 9190245
[TBL] [Abstract][Full Text] [Related]
10. Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol.
Fadda G
Minerva Med; 2001 Aug; 92(4):269-75. PubMed ID: 11535970
[TBL] [Abstract][Full Text] [Related]
11. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept.
Schutz A; Gund HJ; Pschorn U; Aicher B; Peil H; Müller A; de Mey C; Gillissen A
Arzneimittelforschung; 2002; 52(3):194-9. PubMed ID: 11963647
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
[TBL] [Abstract][Full Text] [Related]
13. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease.
John M; Bosse S; Oltmanns U; Schumacher A; Witt C
Respir Med; 2005 Nov; 99(11):1418-24. PubMed ID: 15894479
[TBL] [Abstract][Full Text] [Related]
14. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
Akazawa M; Biddle AK; Stearns SC
Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
[TBL] [Abstract][Full Text] [Related]
15. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
16. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial.
Refai M; Brunelli A; Xiumé F; Salati M; Sciarra V; Socci L; Di Nunzio L; Sabbatini A
Eur J Cardiothorac Surg; 2009 Mar; 35(3):469-73. PubMed ID: 19144532
[TBL] [Abstract][Full Text] [Related]
17. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease.
Schreiber J; Bohnsteen B; Rosahl W
Eur J Med Res; 2002 Mar; 7(3):98-102. PubMed ID: 11953279
[TBL] [Abstract][Full Text] [Related]
18. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.
van der Valk P; Monninkhof E; van der Palen J; Zielhuis G; van Herwaarden C
Am J Respir Crit Care Med; 2002 Nov; 166(10):1358-63. PubMed ID: 12406823
[TBL] [Abstract][Full Text] [Related]
19. Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function.
Ericsson CH; Juhász J; Jönsson E; Mossberg B
Eur J Respir Dis; 1986 Oct; 69(4):248-55. PubMed ID: 3545883
[TBL] [Abstract][Full Text] [Related]
20. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
Votto JJ; Bowen JB; Barton RW; Thrall RS
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
